Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Eve Higginbotham, MD. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :30 News and notes with John and Jim 1:20 The FDA approved STAAR Surgical’s EVO/EVO+ Visian implantable Collamer lens for the correction of myopia and myopia with astigmatism 1:28 News on two new drop treatments for presbyopia, Visus’ Brimochol PF and Allergan/AbbVie’s Vuity 4:56 Ocuphire’s Nyxol reduced pharmacologically induced mydriasis 7:12 Axim Biotechnologies rapid test for dry eye inflammatory biomarker 9:20 Representation in medicine fails to reflect diversifying U.S. population 10:50 Introduction of Eve Higginbotham, MD 12:25 The interview 14:52 The gender recession in corporate advancement during the pandemic 15:50 What will change things and get us to a better place in ophthalmology? 17:20 What needs to change in residency training programs? 20:50 What barriers are there to getting sufficient time in the OR? 24:30 Representation on corporate boards 25:15 How do you get new technologies such as presbyopia drops into the training curriculum? 27:05 The latest innovations in glaucoma 30:42 How MIGS has changed practice 32:15 What is the secret to being able to enjoy golfing? 33:00 Eve J. Higginbotham, SM, MD, ML, is the vice dean for Penn Medicine’s Office of Inclusion, Diversity and Equity, senior fellow, Leonard David Institute for Health Economics and professor of ophthalmology at the University of Pennsylvania. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Higginbotham via email at [email protected]. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.